Background: The relationship between Epstein-Barr virus (EBV) and breast cancer (BC) is controversial. Interleukin-10 (IL-10) and interferon-γ (IFN-γ) are believed to play a critical role in the host's responses to EBV infection, and their genetic variations may modify the association of EBV with BC risk.
Methods: We examined serum levels of EBV viral capsid antigen (VCA) immunoglobulin A (IgA) and nuclear antigen-1 (EBNA-1) IgA along with the polymorphisms of IL-10 rs1800871 and IFN-γ rs2069705 in 354 incident BC cases and 504 age-matched controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariate logistic regression.
Results: VCA IgA and EBNA-1 IgA levels were positively associated with BC risk. IL-10 rs1800871 (TC/CC) was associated with a reduced BC risk (OR, 0.74 [95% CI, 0.55-1.00]) but had no interaction with EBV infection on BC risk. IFN-γ rs2069705 was not directly associated with BC risk but interacted with EBNA-1 IgA on BC risk. Among women with the CC genotype, EBNA-1 IgA seropositivity significantly increased the risk of BC compared to EBNA-1 IgA seronegativity (OR, 5.14 [95% CI, 1.76-14.98]).
Conclusions: These results suggest that EBV may contribute to the risk of BC and that this contribution may be modified by genetic variations in IFN-γ.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/jir710 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of the epidemiology and clinical characteristics of Epstein-Barr virus infection.
J Med Virol
October 2024
Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Article Synopsis
- The Epstein-Barr virus (EBV) is prevalent globally and can cause various diseases, with this study focusing on its epidemiological and clinical aspects in Chongqing, China, over a nine-year period.
- Among 13,584 inpatients, seropositivity rates for different EBV antibodies and DNA showed age-related trends, with high rates of acute infection in younger patients and an overall increased seropositivity with age.
- Common diseases associated with EBV included infectious mononucleosis and pneumonia, particularly in cases of primary infection, while reactivation of the virus was linked to conditions like pneumonia and nasopharyngeal carcinoma.
The Epstein-Barr Virus Nuclear Antigen 1 Variant Associated with Nasopharyngeal Carcinoma Defines the Sequence Criteria for Serologic Risk Prediction.
Clin Cancer Res
November 2024
Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Purpose: Antibodies to select Epstein-Barr virus proteins can diagnose early-stage nasopharyngeal carcinoma (NPC). We have previously shown that IgA against Epstein-Barr virus nuclear antigen 1 (EBNA1) can predict incident NPC in high- and intermediate-risk cohorts 4 years before diagnosis. Here, we tested EBNA1 variants, with mutants, to define the sequence requirements for an NPC risk assay.
View Article and Find Full Text PDFThe serological diagnostic value of EBV-related IgA antibody panels for nasopharyngeal carcinoma: a diagnostic test accuracy meta-analysis.
BMC Cancer
September 2024
Office of Cancer Screening, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Article Synopsis
- - A meta-analysis assessed the effectiveness of nine different serological tests for early detection of nasopharyngeal carcinoma (NPC), which is known for its late diagnosis and poor prognosis.
- - The research reviewed 70 studies involving nearly 12,000 NPC cases and over 34,000 control subjects, focusing on the sensitivity and specificity of the antibody panels related to Epstein-Barr Virus (EBV).
- - Results indicated that combinations of certain antibody tests, like EBNA1-IgA combined with VCA-IgA, showed the highest sensitivity and diagnostic odds ratios, suggesting they may be the most viable options for NPC screening.
Multiplex assays reveal anti-EBV antibody profile and its implication in detection and diagnosis of nasopharyngeal carcinoma.
Int J Cancer
November 2024
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Epstein-Barr virus (EBV) is detected in nearly 100% of nonkeratinizing nasopharyngeal carcinoma (NPC) and EBV-based biomarkers are used for NPC screening in endemic regions. Immunoglobulin A (IgA) against EBV nuclear antigen 1 (EBNA1) and viral capsid antigen (VCA), and recently identified anti-BNLF2b antibodies have been shown to be the most effective screening tool; however, the screening efficacy still needs to be improved. This study developed a multiplex serological assay by testing IgA and immunoglobulin G (IgG) antibodies against representative EBV antigens that are highly transcribed in NPC and/or function crucially in viral reactivation, including BALFs, BNLF2a/b, LF1, LF2, and Zta (BZLF1).
View Article and Find Full Text PDFEBV-IgA antibody responses in endemic and nonendemic populations with nasopharyngeal carcinoma: tumour marker prognostication study and a cross-sectional study.
Ann Med Surg (Lond)
September 2023
Department of Pathology, Vrije Universiteit Amsterdam Amsterdam, The Netherlands.
Nasopharyngeal carcinoma (NPC) is the most prevalent head and neck cancer in Indonesia, with 100% Epstein-Barr virus (EBV) infection in tumor cells. NPC is rare in the Netherlands. The involvement of EBV in NPC pathogenesis is reflected by early onset aberrant IgA antibody responses to various EBV proteins.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!